Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC.INO · Entity 6589 | CFO | May 20, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INOVIO PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,854 |
Ending reported balance
After 2026-05-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-20 · Exercise / conversion · Acquired 8,700 · Balance 47,542 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 26,100 restricted stock units was as follows: 8,700 shares vested on May 20, 2026; 8,700 shares will vest on May 20, 2027; 8,700 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Row 2 · 2026-05-20 · Tax withholding · Disposed 4,688 · Balance 42,854 F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 17,400 |
Reported balance
After 2026-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-20 · Exercise / conversion · Disposed 8,700 · Balance 17,400 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 26,100 restricted stock units was as follows: 8,700 shares vested on May 20, 2026; 8,700 shares will vest on May 20, 2027; 8,700 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 32,480 |
Reported balance
After 2026-05-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-20 · Grant · Acquired 32,480 · Balance 32,480 F5: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 10,827 shares will vest on February 26, 2027; 10,827 shares will vest on February 26, 2028; and 10,826 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F6: The restricted stock units were approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the restricted stock units were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026. |
| Common Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.73 · Expires 2036-05-20 | Direct | 39,760 |
Reported balance
After 2026-05-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-20 · Grant · Acquired 39,760 · Balance 39,760 F3: The stock option grant was approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the stock options were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026. F4: The vesting schedule for the options granted on May 20, 2026 was as follows: 13,254 shares will vest on February 26, 2027; 13,253 shares will vest on February 26, 2028; 13,253 shares will vest on February 26, 2029. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 375 |
Reported balance
Holding disclosure · report date 2026-05-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 375 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 26,100 restricted stock units was as follows: 8,700 shares vested on May 20, 2026; 8,700 shares will vest on May 20, 2027; 8,700 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.
F3: The stock option grant was approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the stock options were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026.
F4: The vesting schedule for the options granted on May 20, 2026 was as follows: 13,254 shares will vest on February 26, 2027; 13,253 shares will vest on February 26, 2028; 13,253 shares will vest on February 26, 2029.
F5: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 10,827 shares will vest on February 26, 2027; 10,827 shares will vest on February 26, 2028; and 10,826 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F6: The restricted stock units were approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the restricted stock units were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2019 Filed Mar 12, 2019 21:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 20,433 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-19-000014 · wf-form4_155242479641647.xml · derivative · entry 7 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,433 Underlying: Common Stock · 20,433 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 61,300 restricted stock units is as follows: 20,434 shares vested on March 10, 2018; 20,433 shares vested on March 10, 2019; 20,433 shares will vest on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 61,300 restricted stock units is as follows: 20,434 shares vested on March 10, 2018; 20,433 shares vested on March 10, 2019; 20,433 shares will vest on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 61,300 restricted stock units is as follows: 20,434 shares vested on March 10, 2018; 20,433 shares vested on March 10, 2019; 20,433 shares will vest on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 61,300 restricted stock units is as follows: 20,434 shares vested on March 10, 2018; 20,433 shares vested on March 10, 2019; 20,433 shares will vest on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 10, 2019 Filed Mar 12, 2019 21:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 7,066 | $3.34 | $23,600.44 |
DisclosureSEC source: 0001055726-19-000014 · wf-form4_155242479641647.xml · nonDerivative · entry 4 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,130 F4 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units award reported in footnote (3) herein. Read SEC document |
| March 10, 2019 Filed Mar 12, 2019 21:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 20,433 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-19-000014 · wf-form4_155242479641647.xml · nonDerivative · entry 3 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 61,300 restricted stock units is as follows: 20,434 shares vested on March 10, 2018; 20,433 shares vested on March 10, 2019; 20,433 shares will vest on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 09, 2019 Filed Mar 12, 2019 21:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-19-000014 · wf-form4_155242479641647.xml · derivative · entry 6 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 75,000 restricted stock units was as follows: 25,000 shares vested on March 9, 2017; 25,000 shares vested on March 9, 2018; 25,000 shares vested on March 9, 2019. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 75,000 restricted stock units was as follows: 25,000 shares vested on March 9, 2017; 25,000 shares vested on March 9, 2018; 25,000 shares vested on March 9, 2019. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 75,000 restricted stock units was as follows: 25,000 shares vested on March 9, 2017; 25,000 shares vested on March 9, 2018; 25,000 shares vested on March 9, 2019. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 75,000 restricted stock units was as follows: 25,000 shares vested on March 9, 2017; 25,000 shares vested on March 9, 2018; 25,000 shares vested on March 9, 2019. Read SEC document |
| March 09, 2019 Filed Mar 12, 2019 21:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 8,591 | $3.34 | $28,693.94 |
DisclosureSEC source: 0001055726-19-000014 · wf-form4_155242479641647.xml · nonDerivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,763 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units award reported in footnote (1) herein. Read SEC document |
| March 09, 2019 Filed Mar 12, 2019 21:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-19-000014 · wf-form4_155242479641647.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 75,000 restricted stock units was as follows: 25,000 shares vested on March 9, 2017; 25,000 shares vested on March 9, 2018; 25,000 shares vested on March 9, 2019. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 21:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 64,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-19-000014 · wf-form4_155242479641647.xml · derivative · entry 9 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,400 Underlying: Common Stock · 64,400 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 64,400 restricted stock units is as follows: 21,467 shares will vest on March 8, 2020; 21,467 shares will vest on March 8, 2021; 21,466 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F6 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 64,400 restricted stock units is as follows: 21,467 shares will vest on March 8, 2020; 21,467 shares will vest on March 8, 2021; 21,466 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F6 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 64,400 restricted stock units is as follows: 21,467 shares will vest on March 8, 2020; 21,467 shares will vest on March 8, 2021; 21,466 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 21:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 100,500 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0001055726-19-000014 · wf-form4_155242479641647.xml · derivative · entry 8 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,500 Underlying: Common Stock · 100,500 shares Expires 2029-03-08 F5 · derivative.exercise_date: The vesting schedule for the 100,500 options is as follows: 25,125 shares vested on March 8, 2019; 25,125 shares will vest on March 8, 2020; 25,125 shares will vest on March 8, 2021; 25,125 shares will vest on March 8, 2022. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 22:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 27,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-19-000006 · wf-form4_155199640506740.xml · derivative · entry 4 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,133 Underlying: Common Stock · 27,567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 82,700 restricted stock units is as follows: 27,567 shares vested on March 5, 2019; 27,567 shares will vest on March 5, 2020; 27,566 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 82,700 restricted stock units is as follows: 27,567 shares vested on March 5, 2019; 27,567 shares will vest on March 5, 2020; 27,566 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 82,700 restricted stock units is as follows: 27,567 shares vested on March 5, 2019; 27,567 shares will vest on March 5, 2020; 27,566 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 82,700 restricted stock units is as follows: 27,567 shares vested on March 5, 2019; 27,567 shares will vest on March 5, 2020; 27,566 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 22:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 10,301 | $3.61 | $37,186.61 |
DisclosureSEC source: 0001055726-19-000006 · wf-form4_155199640506740.xml · nonDerivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,354 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being report in this Form 4. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 22:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 27,567 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-19-000006 · wf-form4_155199640506740.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 82,700 restricted stock units is as follows: 27,567 shares vested on March 5, 2019; 27,567 shares will vest on March 5, 2020; 27,566 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| November 29, 2018 Filed Nov 30, 2018 22:27 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 10,001 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001055726-18-000047 · wf-form4_154361682936650.xml · derivative · entry 4 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,001 shares Expires 2018-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F2 · shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F3 · derivative.exercise_date: The shares underlying this option vested and became exercisable on various dates between December 9, 2008 and December 9, 2011. F2 · derivative.underlying_shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. Read SEC document |
| November 29, 2018 Filed Nov 30, 2018 22:27 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 10,001 | $5.28 | $52,805.28 |
DisclosureSEC source: 0001055726-18-000047 · wf-form4_154361682936650.xml · nonDerivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,088 F1 · price: The price reported in Column 4 is a weighted average price. Read SEC document |
| November 29, 2018 Filed Nov 30, 2018 22:27 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 10,001 | $2.00 | $20,002.00 |
DisclosureSEC source: 0001055726-18-000047 · wf-form4_154361682936650.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2018 Filed Jul 11, 2018 21:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 10,000 | $4.45 | $44,500.00 |
DisclosureSEC source: 0001055726-18-000037 · wf-form4_153134308487908.xml · nonDerivative · entry 3 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,088 F2 · price: This transaction was executed in multiple trades at prices ranging from $4.43 to $4.46, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 21:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 15,000 | $0.00 Strike: $4.24 | $0.00 |
DisclosureSEC source: 0001055726-18-000037 · wf-form4_153134308487908.xml · derivative · entry 5 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-07-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F3 · shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F4 · derivative.exercise_date: The shares underlying this option vested and became exercisable on various dates between February 1, 2008 and February 1, 2011. F3 · derivative.underlying_shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 21:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 25,000 | $4.43 | $110,750.00 |
DisclosureSEC source: 0001055726-18-000037 · wf-form4_153134308487908.xml · nonDerivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,088 F1 · price: This transaction was executed in multiple trades at prices ranging from $4.42 to $4.43, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 21:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 15,000 | $4.24 | $63,600.00 |
DisclosureSEC source: 0001055726-18-000037 · wf-form4_153134308487908.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2018 Filed Mar 13, 2018 22:38 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 20,434 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-18-000010 · wf-form4_152098070487312.xml · derivative · entry 7 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,866 Underlying: Common Stock · 20,434 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 61,300 restricted stock units is as follows: 20,434 shares vested on March 10, 2018; 20,433 shares will vest on March 10, 2019; 20,433 shares will vest on March 10, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 61,300 restricted stock units is as follows: 20,434 shares vested on March 10, 2018; 20,433 shares will vest on March 10, 2019; 20,433 shares will vest on March 10, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 61,300 restricted stock units is as follows: 20,434 shares vested on March 10, 2018; 20,433 shares will vest on March 10, 2019; 20,433 shares will vest on March 10, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 61,300 restricted stock units is as follows: 20,434 shares vested on March 10, 2018; 20,433 shares will vest on March 10, 2019; 20,433 shares will vest on March 10, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 10, 2018 Filed Mar 13, 2018 22:38 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 6,899 | $4.51 | $31,114.49 |
DisclosureSEC source: 0001055726-18-000010 · wf-form4_152098070487312.xml · nonDerivative · entry 4 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,088 F4 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (3) herein. Read SEC document |
| March 10, 2018 Filed Mar 13, 2018 22:38 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 20,434 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-18-000010 · wf-form4_152098070487312.xml · nonDerivative · entry 3 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 61,300 restricted stock units is as follows: 20,434 shares vested on March 10, 2018; 20,433 shares will vest on March 10, 2019; 20,433 shares will vest on March 10, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 22:38 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-18-000010 · wf-form4_152098070487312.xml · derivative · entry 6 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 75,000 restricted stock units is as follows: 25,000 shares vested on March 9, 2017; 25,000 shares vested on March 9, 2018; 25,000 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 75,000 restricted stock units is as follows: 25,000 shares vested on March 9, 2017; 25,000 shares vested on March 9, 2018; 25,000 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 75,000 restricted stock units is as follows: 25,000 shares vested on March 9, 2017; 25,000 shares vested on March 9, 2018; 25,000 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 75,000 restricted stock units is as follows: 25,000 shares vested on March 9, 2017; 25,000 shares vested on March 9, 2018; 25,000 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 22:38 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 8,421 | $4.51 | $37,978.71 |
DisclosureSEC source: 0001055726-18-000010 · wf-form4_152098070487312.xml · nonDerivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,553 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 22:38 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-18-000010 · wf-form4_152098070487312.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 75,000 restricted stock units is as follows: 25,000 shares vested on March 9, 2017; 25,000 shares vested on March 9, 2018; 25,000 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2018 Filed Mar 8, 2018 00:43 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 82,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-18-000004 · wf-form4_152046977390477.xml · derivative · entry 6 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,700 Underlying: Common Stock · 82,700 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 82,700 restricted stock units is as follows: 27,567 shares will vest on March 5, 2019; 27,567 shares will vest on March 5, 2020; 27,566 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 82,700 restricted stock units is as follows: 27,567 shares will vest on March 5, 2019; 27,567 shares will vest on March 5, 2020; 27,566 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 82,700 restricted stock units is as follows: 27,567 shares will vest on March 5, 2019; 27,567 shares will vest on March 5, 2020; 27,566 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2018 Filed Mar 8, 2018 00:43 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 126,500 | $0.00 Strike: $4.29 | $0.00 |
DisclosureSEC source: 0001055726-18-000004 · wf-form4_152046977390477.xml · derivative · entry 5 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,500 Underlying: Common Stock · 126,500 shares Expires 2028-03-05 F3 · derivative.exercise_date: The vesting schedule for the 126,500 options is as follows: 31,625 shares vested on March 5, 2018; 31,625 shares will vest on March 5, 2019; 31,625 shares will vest on March 5, 2020; 31,625 shares will vest on March 5, 2021. Read SEC document |
| March 05, 2018 Filed Mar 8, 2018 00:43 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 8,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-18-000004 · wf-form4_152046977390477.xml · derivative · entry 4 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 25,000 restricted stock units was as follows: 8,334 shares vested on March 5, 2016; 8,333 shares vested on March 5, 2017; 8,333 shares vested on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 25,000 restricted stock units was as follows: 8,334 shares vested on March 5, 2016; 8,333 shares vested on March 5, 2017; 8,333 shares vested on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 25,000 restricted stock units was as follows: 8,334 shares vested on March 5, 2016; 8,333 shares vested on March 5, 2017; 8,333 shares vested on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 25,000 restricted stock units was as follows: 8,334 shares vested on March 5, 2016; 8,333 shares vested on March 5, 2017; 8,333 shares vested on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2018 Filed Mar 8, 2018 00:43 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 3,407 | $4.29 | $14,616.03 |
DisclosureSEC source: 0001055726-18-000004 · wf-form4_152046977390477.xml · nonDerivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,974 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 05, 2018 Filed Mar 8, 2018 00:43 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 8,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-18-000004 · wf-form4_152046977390477.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 25,000 restricted stock units was as follows: 8,334 shares vested on March 5, 2016; 8,333 shares vested on March 5, 2017; 8,333 shares vested on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 10, 2017 Filed Mar 13, 2017 21:40 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 61,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-17-000007 · wf-form4_148944124044588.xml · derivative · entry 6 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,300 Underlying: Common Stock · 61,300 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 61,300 restricted stock units is as follows: 20,433 shares will vest on March 10, 2018; 20,434 shares will vest on March 10, 2019; 20,433 shares will vest on March 10, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 61,300 restricted stock units is as follows: 20,433 shares will vest on March 10, 2018; 20,434 shares will vest on March 10, 2019; 20,433 shares will vest on March 10, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 61,300 restricted stock units is as follows: 20,433 shares will vest on March 10, 2018; 20,434 shares will vest on March 10, 2019; 20,433 shares will vest on March 10, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 10, 2017 Filed Mar 13, 2017 21:40 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 100,000 | $6.68 Strike: $6.68 | $668,000.00 |
DisclosureSEC source: 0001055726-17-000007 · wf-form4_148944124044588.xml · derivative · entry 5 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-03-10 F2 · derivative.exercise_date: The vesting schedule for the 100,000 options is as follows: 25,000 shares vested on March 10, 2017; 25,000 shares will vest on March 10, 2018; 25,000 shares will vest on March 10, 2019; 25,000 shares will vest on March 10, 2020 Read SEC document |
| March 09, 2017 Filed Mar 13, 2017 21:40 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-17-000007 · wf-form4_148944124044588.xml · derivative · entry 4 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 75,000 restricted stock units is as follows: 25,000 shares vested on March 9, 2017; 25,000 shares will vest on March 9, 2018; 25,000 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 75,000 restricted stock units is as follows: 25,000 shares vested on March 9, 2017; 25,000 shares will vest on March 9, 2018; 25,000 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 75,000 restricted stock units is as follows: 25,000 shares vested on March 9, 2017; 25,000 shares will vest on March 9, 2018; 25,000 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 75,000 restricted stock units is as follows: 25,000 shares vested on March 9, 2017; 25,000 shares will vest on March 9, 2018; 25,000 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 09, 2017 Filed Mar 13, 2017 21:40 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 9,171 | $6.61 | $60,620.31 |
DisclosureSEC source: 0001055726-17-000007 · wf-form4_148944124044588.xml · nonDerivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,048 Read SEC document |
| March 09, 2017 Filed Mar 13, 2017 21:40 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-17-000007 · wf-form4_148944124044588.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 75,000 restricted stock units is as follows: 25,000 shares vested on March 9, 2017; 25,000 shares will vest on March 9, 2018; 25,000 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 21:45 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 3,640 | $6.95 | $25,298.00 |
DisclosureSEC source: 0001055726-17-000004 · wf-form4_148892309316868.xml · nonDerivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,219 Read SEC document |
| March 05, 2017 Filed Mar 7, 2017 21:45 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 8,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-17-000004 · wf-form4_148892309316868.xml · derivative · entry 4 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 8,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 25,000 restricted stock units is as follows: 8,334 shares vested on March 5, 2016; 8,333 shares vested on March 5, 2017; 8,333 shares will vest on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 25,000 restricted stock units is as follows: 8,334 shares vested on March 5, 2016; 8,333 shares vested on March 5, 2017; 8,333 shares will vest on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 25,000 restricted stock units is as follows: 8,334 shares vested on March 5, 2016; 8,333 shares vested on March 5, 2017; 8,333 shares will vest on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 25,000 restricted stock units is as follows: 8,334 shares vested on March 5, 2016; 8,333 shares vested on March 5, 2017; 8,333 shares will vest on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2017 Filed Mar 7, 2017 21:45 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 8,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-17-000004 · wf-form4_148892309316868.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 25,000 restricted stock units is as follows: 8,334 shares vested on March 5, 2016; 8,333 shares vested on March 5, 2017; 8,333 shares will vest on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.